Italian private equity firm Armonia has agreed to exit BioDue in a deal with Riverside, which will acquire a controlling stake in the Italian company specialised in the development, manufacturing and commercialization of food supplements, medical devices and cosmetics.
Fund VI has raised half of its target so far, with the GP seeking to further prove its investment track record throughout 2023
Sponsors remain broadly optimistic despite fundraise bottlenecks and a growing number of LPs faced with tough choices on manager selection
Sale of financial services research group follows process with early discussions between vendor and bidders
GP has raised EUR 150m for the vehicle against a EUR 250m target, with one third already deployed